> Rottapharm Biotech shared phase 2 data on CR4056 in chronic pain associated with osteoarthritis. The trial missed its primary endpoint but generated results to encourage Rottapharm that the drug works in patients with a certain phenotype. Release
> Themis Bioscience began a phase 1 trial of its Zika virus vaccine. Statement
> Eisai struck a deal with Numab top develop multispecific antibody cancer immunotherapies. Numab will receive an upfront payment plus milestones. Release
> Novo Holdings and Arix Bioscience co-led a €20 million ($22 million) series A financing in STipe Therapeutics. The funding will support efforts to modulate the STING pathway. Statement
> Genfit appointed Dean Hum as president of its U.S. operation. Hum is relocating to the U.S. Release
> Transgene shared clinical data on TG4001 in combination with Merck KGaA and Pfizer’s anti-PD-L1 immunotherapy. Three of the six HPV-positive cancer patients who received the higher dose of therapeutic vaccine TG4001 experienced durable partial responses. Statement